Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Or Refractory B-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• MS-553 (MS-553)

Snippet

Sponsor: MingSight Pharmaceuticals, Inc | Conditions: Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1, Phase 2 | Status: TERMINATED